Glutaminovaia acid coated tablets 0.25 g. №10


Manufacturer: Ukraine

Treatment of epilepsy, mainly small attacks with equivalents, somatogenic, involutional, intoxicating psychoses, reactive States with symptoms of depression, exhaustion; with mental retardation in children, down’s disease, with cerebral palsy, polio (acute and recovery periods), with progressive myopathy, to eliminate and prevent neurotoxic phenomena that may occur when using isoniazid and other drugs of the isonicotinic acid hydrazide group.



Glutaminovaia acid Composition
active substance: 1 tablet contains L-glutamic acid 250 mg;

excipients: potato starch, povidone, stearic acid, calcium stearate;

shell: sugar, light magnesium carbonate, povidone, colloidal anhydrous silica, talc, titanium dioxide (E 171), patented blue dye V (E 131), yellow wax, light mineral oil.

Glutaminovaia acid Dosage form

Coated tablets.

Main physical and chemical properties: round tablets with a biconvex surface, coated with a blue shell. In cross section, two layers are visible. Sprinkles are allowed on the surface of the tablets.

Glutaminovaia acid Pharmacotherapeutic group

Drugs acting on the nervous system. ATX code N07X X.

Pharmacological properties


A substitute amino acid that participates in the processes of amino acid reamination in the body, in protein and carbohydrate metabolism, stimulates oxidative processes, promotes neutralization and excretion of ammonia, increases the body’s resistance to hypoxia. Promotes the synthesis of acetylcholine and ATP, the transfer of potassium ions, plays an important role in skeletal muscle activity. Glutamic acid is a neurotransmitter amino acid that stimulates the transmission of excitation at the synapses of the central nervous system.


Glutamic acid is well absorbed when taken orally. It is rapidly eliminated from the blood, accumulating mainly in muscle and nerve tissues, liver and kidneys, penetrates the blood-brain barrier and cell membranes. Partially glutamic acid during absorption is reaminated to form alanine. Under the influence of the enzyme glutamate decarboxylase is converted in the brain into a mediator – gamma-aminobutyric acid.

About 4-7% of it is excreted in the urine unchanged, the rest is utilized in the process of metabolic transformations.

Treatment of epilepsy, mainly small seizures with equivalents, somatogenous, involutional, intoxication psychoses, reactive states with the phenomena of depression, exhaustion; with mental retardation in children, Down’s disease, cerebral palsy, poliomyelitis (acute and recovery periods), with progressive myopathy, to eliminate and prevent neurotoxic effects that may occur with the use of isoniazid and other drugs of the acid hydroside group isoniko.

Fever, hyperexcitability, severe psychotic reactions, hepatic and / or renal failure, nephrotic syndrome, gastric and duodenal ulcers, hematopoietic diseases, anemia, leukopenia.

Interaction with other medicinal products and other forms of interaction

Co-administration of thiamine and pyridoxine (B vitamins) Glutamic acid can be used for the prevention and treatment of neurotoxic effects caused by the patient’s use of Ginkgo drugs (isonicotinic acid hydrazide, such as ftivazide, isoniazid).

In myopathy and muscular dystrophy, glutamic acid is more effective in combination with pachycarpine or glycocol.